Navigation Links
Major breakthrough may pave the way for therapeutic vaccines

It should be possible to use therapeutic vaccines to create both cheap and effective drugs for diseases like cancer and allergies. One problem in developing such vaccines has previously been the lack of adjuvants, substances that make vaccines more effective. However, there has now been a major breakthrough in this area. The study, led by scientists at Uppsala University, is published in the December issue of the journal Vaccine.

Many of the treatment methods that are developed today for allergies, cancer, and autoimmune diseases are based on the use of so-called monoclonal antibodies. The cost of these protein pharmaceuticals is high, between 15 000 and 150 000 dollars per patient and year, and long periods of treatment are often needed. Therapeutic vaccines contain no pre-produced antibodies but rather stimulate our immune system to produce its own therapeutic antibodies. They are considerably less expensive to manufacture than the drugs that are now being produced.

"Therapeutic vaccines that target the same molecules in the body as the various monoclonal antibodies would enable us to reduce the cost of treatment significantly, and also decrease the number of visits patients need to make to the clinic," says Lars Hellman, professor of molecular and comparative immunology at the Department of Cell and Molecular Biology, Uppsala University, who directed the study.

One of the biggest problems when it comes to developing therapeutic vaccines has been the lack of so-called adjuvants, immune-stimulating substances that are added to boost the effect of the vaccine. Until now, there has been only one adjuvant that is approved for use in humans, and this substance has proven to have little or no effect when the target molecule is endogenous, that is, produced by the body itself. To develop new and more potent adjuvants, researchers from Uppsala University, in collaboration with colleagues from the Shemyakin-Ovchinnikov Institute in Moscow, have performed comprehensive analyses of various potential combinations.

"We have made a very important breakthrough by managing to identify a substance that is biologically degradable and that exhibits considerably higher activity than the adjuvants that have been used in the past," says Lars Hellman.

"These new and highly promising findings are an important step toward developing more cost-effective drugs for some of our major public health diseases," he says.


Contact: Lars Hellman
Uppsala University

Related biology news :

1. Oscar Pistorius artificial limbs give him clear, major advantage for sprint running
2. Oberthur Technologies: Major Security Certifications for the Identity Product Range
3. LSU ichthyologist lands major grant to study fish family history
4. USU scientists report major advance in human antibody therapy against deadly Nipah virus
5. NSF grant supports Rutgers-Camden program for science majors
6. A major step in making better stem cells from adult tissue
7. Major discovery opens door to leishmania treatment
8. How mitochondrial gene defects impair respiration, other major life functions
9. BioConference Live Attracts Major Life Science Sponsors
10. Restoring a natural root signal helps to fight a major corn pest
11. Family planning a major environmental impact
Post Your Comments:
(Date:10/26/2015)... October 26, 2015 ... adds Biometrics Market Shares, ... as well as Emerging Biometrics Technologies: ... to its collection of IT and ... . --> ...
(Date:10/23/2015)... -- Research and Markets ( ) has announced ... Market 2015-2019" report to their offering. ... voice recognition biometrics market to grow at a CAGR ... --> The report, Global Voice Recognition ... in-depth market analysis with inputs from industry experts. The ...
(Date:10/22/2015)... SAN JOSE, Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ... results for its first quarter ended September 30, 2015. ... first quarter of fiscal 2016 grew 66 percent over the comparable ... quarter of fiscal 2016 was $23.8 million, or $0.62 per diluted ... net income for the first quarter of fiscal 2016 grew 39 ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... ... 2015 , ... A long-standing partnership between the Academy of ... formalized with the signing of a Memorandum of Understanding. , AMA Executive Director ... Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters in ...
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
Breaking Biology Technology: